Funding round
Arsenal Bio Series A
Arsenal Bio, which works in programmable cell therapy development in South San Francisco, raised $85M in a Series A round announced on 17 Oct 2019. 6 firms took part. It is Arsenal Bio's first venture round on record.
$85M
Amount raised
Not disclosed
Post-money valuation
6
Investors
no lead named
Valuation
What this round says about the price
Arsenal Bio did not disclose a valuation in this round. It is Arsenal Bio's first venture round on record, in the year it was founded (2019). It is 13% of the $630M Arsenal Bio has raised in the venture rounds on record. Arsenal Bio raised again 35 months later: a Series B round of $220M in Sep 2022.
Investors
Who put money in
6 firms took part; no lead investor was named.
Investors
- backs 11 venture-backed companies new investor
- Parker Institute for Cancer Immunotherapy new investor
- Kleiner Perkins backs 285 venture-backed companies new investor
- backs 2 venture-backed companies new investor
- Euclidean Capital new investor
- Osage University Partners new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
90 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $14M, and this round was 6.1 times the median. The closest in time, other companies' Series A rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 31 Oct 2019 | $14M | not disclosed | OneVentures and IP Group |
| Biotechnology | 15 Oct 2019 | $13M | not disclosed | Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr |
| Biotechnology | 22 Oct 2019 | $10M | not disclosed | Lux Capital and Obvious |
| Biotechnology | 24 Oct 2019 | $5.0M | not disclosed | The Chartered Group |
| Biotechnology | 31 Oct 2019 | undisclosed | not disclosed | not named |
| Biotechnology | 5 Nov 2019 | $57M | not disclosed | The Column Group |
| Biotechnology | 21 Nov 2019 | $39M | not disclosed | Leaps by Bayer and Novartis Venture Fund |
| Biotechnology | 23 Sep 2019 | $26M | not disclosed | CMB International Capital Corporation |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Arsenal Bio raise in its Series A round?
Arsenal Bio raised $85M in its Series A round, announced in Oct 2019.
Which investors took part in Arsenal Bio's Series A round?
Westlake BioPartners, Parker Institute for Cancer Immunotherapy, Kleiner Perkins, UCSF Foundation Investment Company, Euclidean Capital and Osage University Partners.
What was Arsenal Bio's valuation at the Series A round?
It was not disclosed.
How does it compare with other Series A rounds in Biotechnology?
90 Series A rounds in Biotechnology within a year either side disclosed an amount; the median was $14M, and this round was 6.1 times the median.
Did Arsenal Bio raise again after this round?
Yes: a Series B round in Sep 2022 of $220M.